Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 12/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169117 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HSD11B1MAPTPRMT5 | |
| SCHEMBL2169112 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HSD11B1MAPTPRMT5 | |
| SCHEMBL12012565 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HSD11B1MAPTPRMT5 | |
| SCHEMBL12012578 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HSD11B1MAPTPRMT5 | |
| SCHEMBL2168528 | 0.88 | HSD11B1 (0.51) | HSD11B1PRMT5WDR77 | |
| SCHEMBL12012566 | 0.88 | HSD11B1 (0.51) | HSD11B1PRMT5WDR77 | |
| SCHEMBL2168876 | 0.88 | HSD11B1 (0.51) | HSD11B1PRMT5WDR77 | |
| SCHEMBL12012577 | 0.88 | HSD11B1 (0.51) | HSD11B1PRMT5WDR77 | |
| SCHEMBL2168531 | 0.88 | HSD11B1 (0.51) | HSD11B1PRMT5WDR77 | |
| SCHEMBL2169585 | 0.87 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HSD11B1MAPTPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 157/4885SMN1; SMN2 3043/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.